A single first RMD can push a retiree two IRMAA brackets higher, jumping Medicare Part B premiums from $203 to $406 per month.
IRMAA brackets work as cliffs, meaning that crossing a threshold by even $1 triggers the full surcharge for the entire year based on income from two years prior.
Qualified Charitable Distributions and pre-RMD Roth conversions are the primary tools retirees use to reduce IRMAA exposure before distributions begin.
Two retirees, same $1 million, same 4% rule, buy one finished with $1.4 million, the other hit $0 in 12 years. Our free reader guide explains the flaw that separated them, and the income-first method built to avoid it.
The standard 2026 Medicare Part B premium is $202.90 a month, up from $185.00 in 2025, and for most beneficiaries, that number is the whole story. For a retiree who took his first Required Minimum Distribution in December and watched it land on top of his other income, the figure that arrived from Social Security was different: $405.80 a month. Same coverage, same doctors, two brackets higher on the Income-Related Monthly Adjustment Amount schedule.

#first #part

Cleveland-Cliffs (NYSE:CLF), an integrated flat-rolled steel and iron ore producer, closed at $10.96, up 15.98%. Quarterly results and upbeat guidance drove the gain; investors are watching second-half earnings and third-quarter adjusted EBITDA.
Trading volume reached 64.1 million shares, coming in about 223% above its three-month average of 19.8 million shares.
The S&P 500 (SNPINDEX:^GSPC) fell 1.21% to 7,408, and the Nasdaq Composite (NASDAQINDEX:^IXIC) fell 2.15% to 25,138. Among other domestic flat-rolled steel manufacturing names, Nucor (NYSE:NUE) closed at $241.15, up 2.23%, while Steel Dynamics (NASDAQ:STLD) closed at $240.57, up 0.81%, highlighting firmer trading in domestic steel peers.
Cleveland-Cliffs confirmed today that the domestic steel market is thriving. Revenue improved both sequentially and year over year as steel pricing and demand remain strong.
Cliffs saw free cash flow turn positive with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) jumping from $95 million in Q1 to $286 million in Q2. Management expects it to approximately double to $575 million in the third quarter.
The company isn't alone in seeing strength in the sector. Last week, Steel Dynamics posted strong Q2 profit and record shipments, reinforcing domestic pricing strength. Sector leader Nucor will announce its second-quarter results next week. Investors can likely expect more of the same.

#steel #cliffs #closed #quarter

Our **** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Management attributes the Q2 EBITDA tripling to the materialization of three strategic pillars: automotive volume recovery, footprint optimization, and the expiration of uneconomic legacy supply contracts.
Automotive shipments reached a two-year high, allowing finishing lines to return to healthy utilization levels and improving unit cost absorption.
The company credits Section 232 and recent trade enforcement for accelerating domestic manufacturing investment and eliminating 'escape valves' for transshipped steel from Mexico and Canada.
Management **** erts that Cleveland-Cliffs has become the 'supplier of choice' for the U.S. auto sector, claiming market share gains from both domestic integrated competitors and mini-mills.

#management #domestic #NVIDIA #Mexico

Medicare sets premiums using your MAGI from two years prior, so a $350,000 pension lump sum can spike Part B costs from $203 to $649 monthly.
IRMAA surcharges act as cliffs, where crossing a threshold by just $1 triggers the full penalty and costs Frank roughly $6,400 in a single year.
A trustee-to-trustee IRA rollover keeps a pension buyout out of MAGI entirely, spreading taxable income over years to stay below IRMAA thresholds.
Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.
He retired at 65 from a machine parts company that offered him a choice: a monthly pension check for life, or a one-time cash buyout of roughly $350,000. He took the lump sum. It felt safer to control the money himself, and the company had been shaky for years. He rolled some into an IRA, kept a chunk in a taxable brokerage account for a kitchen remodel, and started Social Security at 66.

#monthly

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
Novartis said second-quarter sales inched upward, beating **** yst expectations for a decline as demand for newer products helped offset generic competition for its former top-selling heart medication Entresto.
At constant exchange rates, net sales increased 1% to $14.4 billion, Novartis said Tuesday. That beat the consensus estimate of about $13.7 billion, Jefferies **** yst Michael Leuchten wrote in a note to clients. Core operating income reached $5.94 billion, topping the consensus estimate of $5.31 billion. Leuchten had expected core operating income of $5.16 billion on sales of $13.8 billion.
The Swiss drugmaker highlighted increases of more than 30% for "priority brands" including Kisqali, Kesimpta, Scemblix, Pluvicto and Leqvio. Revenue from Entresto plunged by half to $1.18 billion in the period, moving the drug down to fourth place on the list of Novartis' most lucrative products.
Already buffeted by Entresto losses in the U.S., Novartis is looking ahead to one of the most daunting patent cliffs in the pharmaceutical industry over the next five years, affecting all four of its top-selling medicines in the second quarter. Entresto is set to lose exclusivity in Europe in 2028. After that, U.S. patent expirations follow for its biggest moneymaker, Cosentyx, in 2029 and both Kesimpta and Kisqali in 2031.

#billion #biopharma #dive

Just when we thought things were going in a good direction, tensions in the Middle East escalated again. If things worsen, it may eventually impact broader equities. Even if that doesn't happen, it's always useful for investors to buy shares in solid, dividend-paying corporations that can perform relatively well -- and continue raising their payouts -- regardless of economic conditions.
Let's consider two excellent stocks that fit the bill: AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). Both are Dividend Kings, or companies with at least 50 consecutive years of dividend increases. Here's why they are among my favorite stocks in this elite group to buy right now.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
AbbVie, a pharmaceutical leader, boasts a deep portfolio of medicines across several therapeutic areas. The company is best-known for its work in immunology, with its two growth pillars, Skyrizi and Rinvoq, performing even better than management had anticipated. They should maintain sales growth for a while, and by the time they run into patent cliffs, the drugmaker will almost certainly have found new growth drivers. AbbVie is developing promising products, including an investigational weight-loss medicine, ABBV-295, that performed well in early stage studies.
The anti-obesity market is growing rapidly, and AbbVie's candidate could prove a highly differentiated **** et, as it can be administered monthly (the current leaders are taken weekly).

Just when we thought things were going in a good direction, tensions in the Middle East escalated again. If things worsen, it may eventually impact broader equities. Even if that doesn't happen, it's always useful for investors to buy shares in solid, dividend-paying corporations that can perform relatively well -- and continue raising their payouts -- regardless of economic conditions.
Let's consider two excellent stocks that fit the bill: AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). Both are Dividend Kings, or companies with at least 50 consecutive years of dividend increases. Here's why they are among my favorite stocks in this elite group to buy right now.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
AbbVie, a pharmaceutical leader, boasts a deep portfolio of medicines across several therapeutic areas. The company is best-known for its work in immunology, with its two growth pillars, Skyrizi and Rinvoq, performing even better than management had anticipated. They should maintain sales growth for a while, and by the time they run into patent cliffs, the drugmaker will almost certainly have found new growth drivers. AbbVie is developing promising products, including an investigational weight-loss medicine, ABBV-295, that performed well in early stage studies.
The anti-obesity market is growing rapidly, and AbbVie's candidate could prove a highly differentiated ***** et, as it can be administered monthly (the current leaders are taken weekly).

Teachers can stack a 403(b) and 457(b) under separate IRS ceilings, sheltering roughly $49,000 annually from federal income tax.
Teacher pensions erode via COLA caps as low as 1%, vesting cliffs up to 10 years, and geography gaps that gut purchasing power.
The 457(b) uniquely allows penalty-free withdrawals at any age after separation, letting early-retiring teachers bridge income before Social Security begins.
Many financial professionals are salespeople paid on what they push, not whether you end up wealthier. A fiduciary is the opposite. The SEC legally requires them to put your interests first. Advisor.com's free matching tool pairs you with vetted fiduciaries from major national firms, all in under three minutes. See who you match with today.
Your state pension check looks like a safety net until you stack it against real retirement costs. Average annual household expenditures hit $78,535 in 2024, and the Consumer Price Index sits at 333.979 as of May 2026, up 1.6 points in a single month. Most teacher pensions replace a fraction of final salary, and many have weak or capped cost-of-living adjustments. That gap is exactly what the double-stack in your benefits packet was designed to close, and most teachers never open the envelope.

Amid the largest IPO in history, which we recently witnessed, and the booming artificial intelligence industry that continues to show highly attractive prospects, there remain serious economic and geopolitical tensions that could eventually significantly cool much of the excitement on Wall Street. Inflation is on the rise, some economists continue to warn that a recession may be coming, and although the United States and Iran seem to be working toward a deal, it remains hard to predict how that situation will evolve.
In the current environment, it is a good idea to consider investing in dividend stocks. They may not be particularly "exciting" choices right now, but solid dividend payers can help stabilize a portfolio in case the going gets rough and smooth out market losses in a downturn. With that said, let's consider two excellent dividend stocks that are worth investing in right now: Pfizer (NYSE: PFE) and Medtronic (NYSE: MDT). Both healthcare leaders could deliver competitive returns through the next decade.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Pfizer has not performed well in recent years due to poor financial results and upcoming patent cliffs, notably for its anticoagulant Eliquis, one of its best-selling drugs. It will lose patent exclusivity by the end of the decade. However, the company is developing new products that could help it overcome these challenges. Pfizer has significantly expanded its pipeline in recent years, partly thanks to acquisitions, and now boasts a deep portfolio of investigational medicines.
The most promising might be in oncology and weight loss. In the latter therapeutic area, Pfizer is developing an anti-obesity medicine, MET-097i, which it hopes will be highly differentiated from current market leaders, thanks to its better safety profile and long-acting properties.

A Los Angeles mansion is on the market for $135 million following a $60 million price drop.
It was built by Hyatt heir Tony Pritzker and his then-wife, Jeanne, in 2011, but they split in 2022.
The 50,000-square-foot home — one of the country's largest — has 16 bedrooms, 27 bathrooms, and a cliffside pool.
In the hills of Beverly Crest, a neighborhood in Los Angeles' Westside, looms the Pritzker estate, one of the largest homes in the US.
The 50,000-square-foot megamansion took six years to build and includes 16 bedrooms, 27 bathrooms, a tennis court, a basketball court, a cliffside pool, a detached guest house, a bowling alley, and a private movie theater.